AB0356 Advantageous Effect of Small Doses of Atorvastatin on A Chemokines Profile and Clinical Activity of Rheumatoid Arthritis

Background In patients with rheumatoid arthritis (RA) treated with statins it is difficult to establish their pleiotropic, including anti-inflammatory, effect due to the high activity of the inflammatory process in the course of the disease. This concerns, in particular, the daily clinical practice...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.922-922
Hauptverfasser: Rupinski, R., Walewska, E.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background In patients with rheumatoid arthritis (RA) treated with statins it is difficult to establish their pleiotropic, including anti-inflammatory, effect due to the high activity of the inflammatory process in the course of the disease. This concerns, in particular, the daily clinical practice in which small and medium doses of statins are used, for safety reasons. Objectives The aim of the study was to assess the effect of atorvastatin (ATS) treatment in patients with RA on specific complex indices of the disease activity, complex indices of vascular endothelial activation and activity of selected pro-atherogenic chemokines. Methods The observation included a group of 62 RA patients currently treated with methotrexate (women – 93.5%, age – 59.3±7.1 years, disease duration – 8.2±8.0 years, presence of anti-CCP antibodies – 69.8%). 36 patients (studied group, 58.1%) received 16 weeks treatment with ATS (10 mg daily) and dietary recommendations (according to ATP III), and the remaining patients (control group) only dietary recommendations. In all patients the disease activity score (DAS28 with ESR) was calculated, and serum levels of anti-CCP antibodies, chemokines (CX3CL1 – fractalkine, CCL2 – monocyte chemotactic protein-1, CCL5 – RANTES) and soluble endothelial factors (ICAM-1 – intercellular adhesion molecule-1, VEGF – vascular endothelial growth factor) were determined (ELISA, R&D Systems). Each single result (X) was then transformed into a figure in the 0–1 range according to the selected formula (X/mean for the whole group + SD). The following complex indices were established: clinical disease activity (Clin-Score = DAS28 + anti-CCP), vascular endothelial activation (Endo-Score = ICAM-1 + VEGF), chemokines activity (Chemo-Score = CX3CL1 + CCL2 + CCL5) and the mixed index (Mixed-Score = CRP + CCL5 + ICAM-1). The statistical analysis of the atorvastatin treatment effect on the selected complex indices and their components was performed with the Mann-Whitney and Wilcoxon tests (Statistica v. 10). Results Following the ATS treatment, statistically significant reduction in the levels of ICAM-1 (observation baseline and endpoint, 131 pg/ml vs. 111 pg/ml respectively, p
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2014-eular.5838